Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
This is a case of one patient who was treated with a bortezomib-based desensitization regimen to treat sensitization obtained though a previous transplant lost to chronic rejection. This regimen successfully convert a positive crossmatch to negative, prevented both hyperacute and acute rejections out to 3-months post transplant, and was without any noticeable side effects. This account demonstrates that desensitization by bortezomib combined with plasmapheresis and low-dose IVIG is a possible way to transplant a highly sensitized patient.